New Hope For Later Stage Prostate Cancer Patients: The PARP Inhibitor Olaparib Approved By The FDA

Published May 21, 2020

New Hope For Later Stage Prostate Cancer Patients: The PARP Inhibitor Olaparib Approved By The FDA

The FDA has approved PARP Inhibitor Olaparib for the treatment of advanced prostate cancer patients. Experts say this approval marks new personalized therapy options for specific tumors.

NOW
PLAYING
Cancer Doesn't Mean the End—Senator Harry Reid Talks To SurvivorNet About the Experimental New Therapy That Saved His Life
NOW
PLAYING
Molecular Testing Ovarian Cancer
NOW
PLAYING
Ovarian Cancer Treatment Advances
NOW
PLAYING
Immunotherapy Drug Keytruda Approved For Colon Cancer Patients With Specific Tumor Abnormalities
NOW
PLAYING
New Hope For Esophageal Cancer Patients -- Immunotherapy Opdivo Approved For Treatment Of Advanced Esophageal Cancer
NOW
PLAYING
Using PARP Inhibitors Earlier in Ovarian Cancer Treatment
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.